First Manhattan
PTGX icon

First Manhattan’s Protagonist Therapeutics PTGX Stock Holding History

First Manhattan’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-55,800
Closed -$441K – 1619
2022
Q2 		$441K Buy
+55,800
New +$675K ﹤0.01% 564
2018
Q3 		– Sell
-128,244
Closed -$861K – 1429
2018
Q2 		$861K Sell
128,244
-16,200
-11% -$124K 0.01% 470
2018
Q1 		$1.24M Sell
144,444
-271,920
-65% -$5.12M 0.01% 406
2017
Q4 		$8.66M Buy
416,364
+399,764
+2,408% +$7.09M 0.05% 207
2017
Q3 		$293K Buy
+16,600
New +$230K ﹤0.01% 610

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan's PTGX Position: Q3 2022 in Review

First Manhattan sold out of Protagonist Therapeutics (PTGX) in Q3 2022, closing a stake of 55,800 shares — an estimated $441K sold.

First Manhattan first reported a position in PTGX in Q3 2017 and held it in 5 quarters. The position peaked at $8.66M in Q4 2017. 130 funds tracked by Wall St. Rank hold PTGX as of Q3 2022.

  • First Manhattan reported no remaining Protagonist Therapeutics position as of Q3 2022 after selling out during the quarter.
  • First Manhattan sold 55,800 Protagonist Therapeutics shares in Q3 2022, an estimated $441K.
  • First Manhattan first reported a position in Protagonist Therapeutics in Q3 2017 and held it in 5 quarters.
  • First Manhattan's Protagonist Therapeutics position peaked at $8.66M in Q4 2017.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.